Advertisement

Topics

Santen and twoXAR Announce Strategic Research Collaboration to Discover New Glaucoma Treatments

07:30 EST 23 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Santen, Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., the specialty ophthalmology company headquartered in Osaka, Japan, and twoXAR, Inc., an artificial intelligence-driven biopharmaceutical company, today announ...

Other Sources for this Article

for twoXAR, Inc.
Colin Sanford, 415-946-1096
csanford@purecommunications.com
or
Santen Pharmaceutical Co., Ltd.
Christopher Hohman, +81-6-4802-9360
ir@santen.co.jp

NEXT ARTICLE

More From BioPortfolio on "Santen and twoXAR Announce Strategic Research Collaboration to Discover New Glaucoma Treatments"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...